CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Sildenafil Citrate +1 moredrug
Likely dose
Sildenafil citrate 100 mg vaginal dose, single administrationAI-extracted
Key inclusion· 1
  • ✓Primary dysmenorrhea with moderate or severe pain (VAS >35)
Key exclusion· 3
  • ✕Secondary dysmenorrhea
  • ✕Any current medication
  • ✕Serious medical condition

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00123162
NCT00123162Phase 2Completed
CompareCT.gov

Sildenafil Citrate in the Treatment of Primary Dysmenorrhea

Milton S. Hershey Medical Center·interventional·Posted Jul 22, 2005·Updated Dec 23, 2015

In Brief

A Phase 2 clinical trial evaluating Sildenafil Citrate and Placebo for Dysmenorrhea. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The primary hypothesis is that a 100mg single dose of sildenafil citrate (Viagra) will have a higher improvement rate when compared to placebo in the treatment of moderate to severe primary dysmenorrhea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysmenorrhea
CountriesCroatia
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2005
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.9 years ago

Interventions

Sildenafil Citratedrug

A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.

Placebodrug

A single vaginal dose of placebo and monitored for 4 hours.